Nebivolol and Verapamil Interaction

Understanding the Nebivolol and Verapamil Interaction

FDA-approved prescribing information for these two drugs flags their combination as a minor-severity interaction. Nebivolol belongs to the Beta-1 Selective Blocker class and Verapamil belongs to the Calcium Channel Blocker class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: These drugs both act on the heart to slow it down and lower blood pressure. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Nebivolol has 7 total documented interactions on file in this dataset, and Verapamil has 57. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Monitor your heart rate regularly and report any symptoms like dizziness or extreme tiredness to your healthcare provider. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Nebivolol or Verapamil based on a web page, speak with your prescriber or pharmacist before making any change.